Table 1. Characteristics of the full study cohort and people prescribed pregabalin, March 2012–February 2018
All active patients
(n = 1 891 623
)
Patients prescribed pregabalin
(n = 114 123
)
n (%)n (%)Percentage of active
patients, % (95% CI)a
Sex
 Female1 087 939 (57.5)68 311 (59.9)6.3 (5.9 to 6.6)
 Male800 676 (42.3)45 769 (40.1)5.7 (5.4 to 6.0)
 Missing3008 (0.2)43 (0.0)1.4 (0.8 to 2.0)
Rurality of patient residence
 Major city1 204 426 (63.7)63 456 (55.6)5.3 (4.9 to 5.6)
 Inner regional440 727 (23.3)33 852 (29.7)7.7 (7.0 to 8.3)
 Outer regional200 543 (10.6)14 706 (12.9)7.3 (6.5 to 8.2)
 Remote29 386 (1.6)1325 (1.2)4.5 (3.2 to 5.8)
 Very remote5932 (0.3)297 (0.3)5.0 (3.4 to 6.6)
 Missing10 609 (0.6)486 (0.4)4.6 (3.9 to 5.3)
Socioeconomic status of patient residence (IRSAD quintiles)
 1 (most disadvantaged)304 870 (16.1)25 821 (22.6)8.5 (7.9 to 9.1)
 2291 603 (15.4)19 685 (17.2)6.8 (6.3 to 7.2)
 3422 368 (22.3)27 975 (24.5)6.6 (6.1 to 7.1)
 4375 468 (19.8)18 461 (16.2)4.9 (4.5 to 5.3)
 5 (least disadvantaged)480 485 (25.4)21 421 (18.8)4.5 (4.0 to 4.9)
 Missing16 829 (0.9)760 (0.7)4.5 (3.8 to 5.2)
  • aConfidence intervals adjusted for clustering.

  • IRSAD
    index of relative socioeconomic advantage and disadvantage